<GlossaryTerm id="CDR0000799077"><TermName>Inrebic</TermName><TermPronunciation>(in-REH-bik)</TermPronunciation><TermDefinition><DefinitionText>A drug used to treat adults with intermediate-risk or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF, and post-essential thrombocythemia MF. It is also being studied in the treatment of other conditions. Inrebic blocks JAK2 and other proteins, which may help keep abnormal blood cells or cancer cells from growing. It is a type of tyrosine kinase inhibitor. Also called fedratinib hydrochloride.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></TermDefinition><MediaLink ref="CDR0000799633" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Inrebic&quot;" language="en" id="_3"/><MediaLink ref="CDR0000799632" type="audio/mpeg" alt="Pronunciation of dictionary term &quot;Inrebic&quot;" language="es" id="_4"/><SpanishTermName>Inrebic</SpanishTermName><SpanishTermDefinition><DefinitionText>Medicamento que se usa para el tratamiento de  adultos con mielofibrosis de riesgo intermedio o alto, incluso la mielofibrosis primaria, la mielofibrosis pospolicitemia vera y la mielofibrosis postrombocitemia esencial. También, está en estudio para el tratamiento de otras afecciones. Inrebic bloquea JAK2 y otras proteínas, lo que quizás ayude a evitar la multiplicación de células sanguíneas anormales o células cancerosas. Es un tipo de inhibidor de tirosina–cinasas. También se llama clorhidrato de fedratinib.</DefinitionText><Dictionary>Cancer.gov</Dictionary><Audience>Patient</Audience></SpanishTermDefinition><DateFirstPublished>2019-08-22</DateFirstPublished><DateLastModified>2021-10-21</DateLastModified><RelatedInformation><RelatedDrugSummaryRef UseWith="en" href="CDR0000799055" url="/about-cancer/treatment/drugs/fedratinibhydrochloride">Fedratinib Hydrochloride</RelatedDrugSummaryRef></RelatedInformation></GlossaryTerm>
